Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) — Net Asset Quality Index
Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) has a Net Asset Quality Index of 45.9% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥6.82 Billion minus total liabilities of CN¥3.69 Billion yields net assets of CN¥3.13 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check 688076 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Net Asset Quality Index Over Time (2013–2025)
This chart shows how Sinopep-Allsino Biopharmaceutical Co. Ltd. A's Net Asset Quality Index has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the index stands at 45.9%, representing net assets of CN¥3.13 Billion against total assets of CN¥6.82 Billion CNY. See Sinopep-Allsino Biopharmaceutical Co. Lt working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Sinopep-Allsino Biopharmaceutical Co. Ltd. A (2013–2025)
The table below presents the year-by-year Net Asset Quality Index for Sinopep-Allsino Biopharmaceutical Co. Ltd. A from 2013 to 2025, covering 13 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Sinopep-Allsino Biopharmaceutical Co. Lt market cap and net worth.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 44.5% | CN¥3.00 Billion | CN¥6.74 Billion | CN¥3.74 Billion | ▼ -8.3 pp |
| 2024 | 52.8% | CN¥2.68 Billion | CN¥5.08 Billion | CN¥2.40 Billion | ▼ -8.9 pp |
| 2023 | 61.7% | CN¥2.19 Billion | CN¥3.55 Billion | CN¥1.36 Billion | ▼ -14.6 pp |
| 2022 | 76.3% | CN¥1.92 Billion | CN¥2.52 Billion | CN¥597.41 Million | ▼ -8.7 pp |
| 2021 | 85.0% | CN¥1.81 Billion | CN¥2.13 Billion | CN¥318.14 Million | ▲ +15.8 pp |
| 2020 | 69.2% | CN¥966.02 Million | CN¥1.40 Billion | CN¥429.55 Million | ▲ +1.8 pp |
| 2019 | 67.4% | CN¥838.98 Million | CN¥1.24 Billion | CN¥405.54 Million | ▼ -7.3 pp |
| 2018 | 74.7% | CN¥785.38 Million | CN¥1.05 Billion | CN¥265.47 Million | ▲ +22.2 pp |
| 2017 | 52.5% | CN¥321.20 Million | CN¥611.47 Million | CN¥290.27 Million | ▲ +30.7 pp |
| 2016 | 21.8% | CN¥34.95 Million | CN¥160.11 Million | CN¥125.16 Million | ▼ -15.4 pp |
| 2015 | 37.3% | CN¥73.32 Million | CN¥196.67 Million | CN¥123.35 Million | ▲ +51.4 pp |
| 2014 | -14.2% | CN¥-21.47 Million | CN¥151.58 Million | CN¥173.05 Million | ▼ -16.4 pp |
| 2013 | 2.2% | CN¥3.69 Million | CN¥166.81 Million | CN¥163.12 Million | — |